The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Gilead Sciences Inc

Nasdaq: GILD
Last

(U.S.) $107.78

Today's change-0.21 -0.19%
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.
 

Gilead Sciences Inc

Nasdaq: GILD
Last

(U.S.) $107.78

Today's change-0.21 -0.19%
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.

Gilead Sciences Inc down (U.S.)$0.21

Gilead Sciences Inc closed lower Friday, dropping (U.S.)$0.21 or 0.19% to (U.S.)$107.78. Over the last five days, shares have gained 2.33% and 14.34% year to date. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $106.96
  • Previous close(U.S.) $107.99
  • High(U.S.) $108.79
  • Low(U.S.) $106.78
  • Bid / Ask-- / --
  • YTD % change+14.34%
  • Volume10,755,918
  • Average volume (10-day)13,771,316
  • Average volume (1-month)11,448,355
  • Average volume (3-month)10,753,898
  • 52-week range(U.S.) $85.95 to (U.S.) $123.37
  • Beta0.82
  • Trailing P/E11.32×
  • P/E 1 year forward9.22×
  • Forward PEG0.56×
  • Indicated annual dividend(U.S.) $1.72
  • Dividend yield1.60%
  • Trailing EPS(U.S.) $9.53
Updated August 28 4:15 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+51.43%

Based on its net profit margin of 51.43%, Gilead Sciences Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue8,2447,5947,3146,042
Total other revenue--------
Total revenue8,2447,5947,3146,042
Gross profit7,2466,7116,2515,055
Total cost of revenue9988831,063987
Total operating expense2,6282,2232,9842,563
Selling / general / administrative812643876945
Research & development8186941,045630
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--3----
Other operating expenses, total--------
Operating income5,6165,3714,3303,479
Interest income (expense), net non-operating-140-153-130-103
Gain (loss) on sale of assets--------
Other--------
Income before tax5,5115,2394,2303,371
Income after tax4,4974,3323,4622,724
Income tax, total1,014907768647
Net income4,4924,3333,4872,731
Total adjustments to net income--------
Net income before extra. items4,4924,3333,4872,731
Minority interest-51257
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,4924,3333,4872,731
Inc. avail. to common incl. extra. items4,4924,3333,4872,731
Diluted net income4,4924,3333,4872,731
Dilution adjustment--------
Diluted weighted average shares1,5401,5691,6011,637
Diluted EPS excluding extraordinary itemsvalue per share2.922.762.181.67
Dividends per sharevalue per share0.430.000.000.00
Diluted normalized EPSvalue per share2.922.762.181.67